José Luís Passos‐Coelho

Author

Instituto Português de Oncologia de Coimbra Francisco Gentil ORCID

Also Known As

Coelho, José Luís Castelo Passos, D Ritchie, J L Passos-Coelho, J PASSOSCOELHO, J Passos-Coelho, J. L. Passos-Coelho, J. L. Passos‐Coelho, J. Passos-Coelho, J.L. PASSOS-COELHO, J.L. Passos-Coelho

112

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Instituto Português de Oncologia de Coimbra Francisco Gentil Johns Hopkins University IPO Porto Hospital Beatriz Ângelo Hospital da Luz

About

José Luís Passos‐Coelho is an author at Instituto Português de Oncologia de Coimbra Francisco Gentil specializing in oncology, medicine, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	658
2	Health Sciences	3	3	73
3	Nursing	1	1	35
4	Public Health	1	1	35
5	Biomedical Engineering	1	1	44

José Luís Passos‐Coelho

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer Mafalda Oliveira, Cristina Saura, Paolo Nucíforo, Annals of Oncology Breast OncologyPhase Ii TrialMedicinePharmacologyClinical Trials	2019	149
The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis Sofía Braga, Ana Miranda, Rute Fonseca, Psycho-Oncology	2007	112
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO Xavier Pivot, Andreas Schneeweiß, Shailendra Verma, European Journal of Cancer Metastatic Breast CancerBreast OncologyElderly PatientsMedicineCancer Management	2011	108
Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Tai‐Lin Chen, José Luís Passos‐Coelho, D A Noe, PubMed Nonlinear PharmacokineticsMetastatic Breast CancerPharmacokinetic ModelingMedicinePharmacology	1995	103
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) Robert E. Coleman, Michelle Collinson, Walter M. Gregory, Journal of bone oncology	2018	100
Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. José Luís Passos‐Coelho, H. Braine, Janice M. Davis, Journal of Clinical Oncology	1995	91
Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab Mafalda Oliveira, Sofía Braga, José Luís Passos‐Coelho, Breast Cancer Research and Treatment	2011	72
Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor José Luís Passos‐Coelho, AA Ross, TJ Moss, Blood	1995	59
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer Zhen Shi, Julia Wulfkuhle, Małgorzata Nowicka, Clinical Cancer Research	2021	52
Human mammaglobin RT-PCR assay for detection of occult breast cancer cells in hematopoietic products Ana Luísa Silva, Miguel Tomé, A.E. Correia, Annals of Oncology Breast OncologyOncologyRt-pcr AssayCancer DetectionMedicine	2002	49

Page 1